FDA accepts new drug application for donidalorsen
The FDA accepted a new drug application for review of donidalorsen, a prophylactic RNA-targeting drug used to prevent hereditary angioedema attacks in patients aged 12 years and older, according to a press release from Ionis.“Hereditary angioedema (HAE) is a rare genetic disease where patients experience recurring and unpredictable attacks of severe swelling, which can be